JPRN-UMIN000026606已完成未知
Phase I/II Study of Weekly Paclitaxel and Carboplatin with Concurrent Radiation Therapy in Locally Advanced Non-Small-Cell Lung Cancer. Kansai Clinical Oncology Group KCOG T-0401 - Weekly Paclitaxel and Carboplatin with Concurrent Radiation Therapy in Locally Advanced Non-Small-Cell Lung Cancer.
Kansai Clinical Oncology Group0 个研究点目标入组 40 人开始时间: 2017年3月21日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •pulmonary fibrosis requiring oxygen therapy, myocardial infarction that occurred during the prior six months, liver cirrhosis, active haemorrhage of the digestive tract, mental disorder requiring treatment, diabetes mellitus in poor control, paresis of the intestine ileus, active infection, case with a history of radiation in the fields of radiation, allergy to polyoxyethylene component preparation, peripheral neuropathy, and pregnancy. Cases that a physician judged to be inadequate were also excluded.
研究者
相似试验
招募中
2 期
Phase II study of Weekly Paclitaxel+Weekly Carboplatin for Platinum/Taxan sensitive recurrent mullerian carcinomaJPRN-UMIN000003476Japan Kanto Tumor Board(JKTB)65
已完成
1 期
A Phase I Study of Weekly Nab-Paclitaxel/Carboplatin in Chemotherapy-Naive Patients with Advanced Non-Small-Cell Lung Cancerpreviously untreated advanced non-small cell lung cancerJPRN-UMIN000012788Department of Respiratory Medicine in Hyogo Prefectural Amagasaki Hospital30
已完成
2 期
Phase II Study of Paclitaxel and Carboplatin plus Bevacizumab in StageIIIA-N2, IIIB, IV patients with Nonsquamous Non-Small-Cell Lung Cancerchemotherapy-na&iumlve StageIIIA-N2, IIIB, IV patients with nonsquamous non-small-cell lung cancerJPRN-UMIN000006809Akita University Graduate School of Medicine31
进行中（未招募）
1 期
A Phase I/II Study of Paclitaxel plus Carboplatin and Durvalumab (MEDI4736) with or without Oleclumab (MEDI9447) for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-negative Breast CancerPreviously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)MedDRA version: 20.0Level: PTClassification code 10006198Term: Breast cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10075566Term: Triple negative breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-004651-23-FRInstitut Jules Bordet180
招募中
1 期
A Phase I/II Study of Paclitaxel plus Carboplatin and Durvalumab (MEDI4736) with or without Oleclumab (MEDI9447) for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-Negative Breast CancerPreviously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)MedDRA version: 20.0Level: LLTClassification code: 10027475Term: Metastatic breast cancer Class: 10029104MedDRA version: 20.0Level: PTClassification code: 10075566Term: Triple negative breast cancer Class: 100000004864MedDRA version: 20.0Level: PTClassification code: 10006198Term: Breast cancer recurrent Class: 100000004864CTIS2024-511850-34-00Institut Jules Bordet209